Evidence map›Paper›PMID 36167065›Full record

ArticleStructure (London, England : 1993)2022

High-resolution crystal structure and chemical screening reveal pantothenate kinase as a new target for antifungal development.

Shalev Gihaz, Peter Gareiss, Jae-Yeon Choi, Isaline Renard, Anasuya Chattopadhyay Pal, Yulia Surovsteva, Joy E Chiu, Jose Thekkiniath, Mark Plummer, William Hungerford and 9 more

Open access · greenAbstract read
In one paragraph

Article in Structure (London, England : 1993), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Frontiers in microbiology · 2024
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Shalev GihazSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Peter GareissYale Center for Molecular Discovery, Yale West Campus, West Haven, CT 06516, USA.
Jae-Yeon ChoiSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Isaline RenardSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Anasuya Chattopadhyay PalSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Yulia SurovstevaYale Center for Molecular Discovery, Yale West Campus, West Haven, CT 06516, USA.
Joy E ChiuSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Jose ThekkiniathSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Mark PlummerSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
William HungerfordYale Center for Molecular Discovery, Yale West Campus, West Haven, CT 06516, USA.
Micaela L MontgomeryDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Alanah HosfordDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Emily M AdamsDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Jorge D LightfootDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
David FoxSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA; UCB Pharma, 7869 NE Day Road West, Bainbridge Island, WA 98110, USA.
Kayode K OjoCenter for Emerging & Re-emerging Infectious Disease, Division of Allergy & Infectious Disease, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
Bart L StakerSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Kevin FullerDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Choukri Ben MamounSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: choukri.benmamoun@yale.edu.
Yale University · USUniversity of Oklahoma Health Sciences Center · USCenter for Infectious Disease Research · USUniversity of Washington · US

Funding

P30-CENTER CORE GRANT FOR VISION RESEARCHP30EY021725 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michelle C Callegan, MICHAEL H ELLIOTT · 2011 to 2026
$10.5M
Fosinopril analogs for the treatment of human babesiosisR01AI153100 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2021 to 2025
$3.6M
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria TreatmentR01AI138139 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BEN MAMOUN, CHOUKRI, LE ROCH, KARINE GAELLE · 2018 to 2022
$3.6M
Development of endochin-like quinolones for babesiosis therapyR01AI123321 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2017 to 2020
$2.7M
Antigen Discovery and Vaccine Development for Human Babesia ParasitesR01AI152220 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2020 to 2024
$2.1M
NEI NIH HHS P30 EY021725NIAID NIH HHS HHSN272201700059CNIAID NIH HHS R01 AI123321NIAID NIH HHS R01 AI138139NIAID NIH HHS R01 AI152220NIAID NIH HHS R01 AI153100
6 · The paper itself

Abstract

Fungal infections are the leading cause of mortality by eukaryotic pathogens, with an estimated 150 million severe life-threatening cases and 1.7 million deaths reported annually. The rapid emergence of multidrug-resistant fungal isolates highlights the urgent need for new drugs with new mechanisms of action. In fungi, pantothenate phosphorylation, catalyzed by PanK enzyme, is the first step in the utilization of pantothenic acid and coenzyme A biosynthesis. In all fungi sequenced so far, this enzyme is encoded by a single PanK gene. Here, we report the crystal structure of a fungal PanK alone as well as with high-affinity inhibitors from a single chemotype identified through a high-throughput chemical screen. Structural, biochemical, and functional analyses revealed mechanisms governing substrate and ligand binding, dimerization, and catalysis and helped identify new compounds that inhibit the growth of several Candida species. The data validate PanK as a promising target for antifungal drug development.

Indexed as

Antifungal AgentsPhosphotransferases (Alcohol Group Acceptor)FungiPantothenic AcidAntifungal Agentspantothenate kinasePantothenic AcidPhosphotransferases (Alcohol Group Acceptor)antifungalsAspergillus fumigatusdrug susceptibilitypantothenate kinaseSaccharomyces cerevisiaevitamin B5

Identifiers

PMID36167065
PMCPMC10042587
OpenAlexW4297143400

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.